STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Peptide

ACE-031

Also known as

ActRIIB-Fc · ACE031 · Ramatercept (related)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Peptide Some talk Systemic SubQ Growth factors / muscle

Systemic activin-pathway biologic (discontinued development).

What people say ACE-031 is a discontinued myostatin/activin-pathway biologic. Forums discuss pumps, leanness and muscle density, but the labeled-vial stories are not equivalent to the early clinical drug. Doses people talk about
Individual labeled-product reports1 mg total / 10 days; 0.5 mg weekly / 4 weeks

Separate 2014 injectable-product accounts; exact injection route unspecified. The weekly account included extensive steroid/secretagogue co-use. Not a progression or proven equivalent of the trial product.

Historical single-dose trial0.02–3 mg/kg SC once

Healthy postmenopausal women. Older ~0.1–3 mg/kg summaries are retained below with their corrected route context; not a bodybuilding dose.

No validated consumer dose; product identity and route uncertainty materially limit forum comparisons.

Half-life & effect duration

Half-life in the body
  • Under-the-skin injectionAbout 10–15 days
Felt duration people report
  • During usePumps without strength gains in one account
  • After stoppingOne stacked-use account claims continued growth for 4 weeks
  • After one doseNo consistent duration reported
Timing context & sources
How it may feel Individual reports describe stronger pumps and sweating, sometimes without strength gains. A dramatic growth account used a large steroid/secretagogue stack; no consistent day-1 feeling is established.
Cycles people discuss There is no validated consumer cycle. A historical weekly 4-week account sits alongside other short experiments; trial dosing was single or intermittent. Weeks-off talk reflects cost and caution, not a proven reset. Timing Training, sleep and side effects shape forum scheduling. The measured 10–15-day SC half-life does not validate workout timing or explain how long a reported pump lasts. Stacks A positive report used several steroids plus CJC no-DAC and GHRP-2. Those combinations obscure attribution; the longer notes do not recommend a stack. Watch for Nosebleeds / telangiectasias: Safety issues contributed to program halt discussions.
Related
BimagrumabApitegromabFollistatin-344

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

10–15 days in the single-dose SC human study.

This is measured ACE-031 drug-product PK, not a class guess or a pump-duration estimate.

Abstract-only review; not measured in male bodybuilders or unregulated products.

  • Single ascending-dose ACE-031 trial in healthy volunteers (opens in a new tab)Attie et al., Muscle Nerve 2013;47:416–423, abstract Methods and Results. Complete abstract read through Europe PMC EXT_ID:23169607 after PubMed returned an empty rendering.Abstract-only; 48 healthy postmenopausal women, single SC dose. Not bodybuilding vial PK, repeated-dose safety or a subjective effect-duration study.

Felt duration people report

No dependable after-dose felt window in the checked accounts.

Reports concern repeated-use changes. One claimed continued growth 4 weeks after stopping amid other hormones; another reported pumps but no strength gain.

Commercial forum setting, unverified products and heavy co-use. Neither persistence nor the clinical half-life isolates a subjective ACE-031 duration.

  • ACE-031 share experiences? (opens in a new tab)andrei221, December 24, 2014 opening report (rendered line 33); Gohard March 21, 2018 comments (lines 45–47, 69–80) inspected for compound/co-use separation.Unverified products and unspecified exact ACE-031 injection route. Small self-selected reports on a commercially oriented forum; later follistatin IM comments are not ACE-031 route evidence.
  • ACE-031 — 2014 personal reports (opens in a new tab)pumped5540, September 27, 2014 post #1 (rendered lines 92–94); Elvia1023 post #2 (103–104).Opening report includes extensive steroid/GH-secretagogue co-use; the reply explicitly advertises a sale. Injection depth unspecified and product identity untested. Persistence claims do not isolate ACE-031.

Other context in this card

  • ACE-031 trial in boys with Duchenne muscular dystrophy (opens in a new tab)Campbell et al., Muscle Nerve 2017;55:458–464, complete abstract Methods, Results and Conclusion, also checked through Europe PMC EXT_ID:27462804.Abstract-only. SC administration every 2–4 weeks; study stopped for epistaxis/telangiectasia concerns. It does not establish a safe recreational regimen or significant functional improvement.

What people say 5

  • Body-comp talk: ACE-031 is discussed for recomp, strength continuity, or soft-tissue recovery depending on class. forum
  • Training confound: PRs and scale changes almost always co-travel with diet phase and programming. anecdote
  • Suppression / lipid chatter in stacks: Hormonal-agent bloodwork and PCT discussions surround some ACE-031 stacks, even when partners are marketed “mild.” ACE-031 is an ActRIIB ligand-trap biologic, not an androgen-receptor SARM; those stack discussions do not demonstrate an ACE-031 suppression profile. forum
  • Cycle thinking: Fixed on/off blocks dominate over indefinite daily use. forum
  • Muscle signals (early): Early studies discussed LBM changes before program stop. trial

Doses people talk about 4

  • Community reality: True drug-product is not a standard gray-market staple; many “ACE-031” listings are suspect. Separate 2014 accounts describe 1 mg total over 10 days and 0.5 mg weekly for 4 weeks; exact injection route was not specified, and the latter involved extensive steroid/secretagogue co-use. These are unverified labeled-product reports, not trial-equivalent doses. forum
  • Frequency: trial designs were intermittent/single-dose escalating, not daily bodybuilding pins. trial
  • Clinical trial scale (historical): Older summaries quoted ~0.1–3 mg/kg and combined intravenous/subcutaneous language. The checked single-dose trial instead reports 0.02–3 mg/kg subcutaneously in healthy postmenopausal women. Its single/infrequent mg/kg research context is not a daily research-chem “mcg chart,” and the checked human trials do not support the IV attribution. trial
  • Framing: ACE-031 (ActRIIB decoy) clinical/experimental myostatin-pathway talk; program discontinued — not a consumer protocol. trial

How it may feel 5

  • Days 1–7: Older generic notes mention injection-site reactions or oral GI/mood shifts before benefits; they do not establish an oral ACE-031 route or a typical onset. Actual reports include stronger pumps and sweating without strength gains; another heavily stacked account claims strength/size change within a week. forum
  • Day 1 and later checks: Route, sting and GI logistics in older generic notes are not a measured ACE-031 response pattern. Personal reports concern pumps, perceived leanness or muscle density over repeated use; product identity and co-use prevent a reliable single-dose felt-duration estimate. forum
  • Days 2–7: Side-effect window for many agents; benefits, if any, are easy to mis-attribute. forum
  • Weeks 1–2: First honest checkpoint in self-logs. forum
  • Historical: Development discontinued — not an active approved therapy. trial

Cycles people discuss 4

  • N/A modern use: No legitimate ongoing consumer protocol. forum
  • Common pattern: Many self-protocols use weeks-on / weeks-off rather than indefinite daily use — cost and caution drive this more than hard science. forum
  • No magic cycle: There is rarely one universal “correct” on/off calendar across forums. forum
  • Reassess: Stop and reassess if adverse effects appear; this is not medical care. forum

Timing 3

  • Timing practicalities: People time doses around side effects, training, and sleep more than perfect PK. forum
  • Measured human SC PK: The checked single-dose trial in healthy postmenopausal women reported mean ACE-031 half-lives of 10–15 days across dose groups. This is parent-biologic kinetics, not the duration of a pump or proof of activity in a gray-market vial. trial
  • Published PK: Where human PK exists it should override forum half-life memes for ACE-031. trial

More on what it is 5

  • Why still discussed: Early muscle-building excitement; cautionary tale for pathway drugs. forum
  • Research posture: Educational summary of public discussion and literature themes only. forum
  • How people talk about it: Forum volume is a popularity signal for ACE-031, not proof it works for you. forum
  • What it is: Soluble ActRIIB decoy (ACE-031) myostatin/activin pathway agent halted in development after safety signals. trial
  • Research only: Not approved advice for self-experimentation; legality and access vary by place. forum

Stacks 2

  • None recommended: Historical compound. A checked positive account combined it with trenbolone, testosterone, drostanolone, oxandrolone, CJC no-DAC and GHRP-2; that stack prevents attribution of growth or persistence to ACE-031 alone. forum
  • Less is clearer: Solo runs make personal n=1 easier to interpret than five-compound blasts. forum

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 6

  • Do not romanticize: Community should treat as high-risk discontinued biologic. forum
  • Injection site (if injected): Redness, itch, lumps, bruise — technique and product quality matter. forum
  • Unknowns: Long-term safety for gray-market preparations is often poorly characterized. forum
  • Stack noise: Sides logged on multi-agent stacks cannot be blamed cleanly on one compound. forum
  • Seek care red flags: Severe allergic reaction, chest pain, neuro changes, or uncontrolled BP/glucose need real medical care — not forum advice. forum
  • Nosebleeds / telangiectasias: Safety issues contributed to program halt discussions. trial

Updated: 2026-08-12

Evidence mix Mostly community / anecdote tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →